Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 10/20 | 0.51 |
| ▸ | HDAC6 | Q9UBN7 | 10/20 | 0.51 |
| ▸ | HDAC8 | Q9BY41 | 4/20 | 0.49 |
| ▸ | TACR1 | P25103 | 6/20 | 0.48 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.47 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.47 |
| ▸ | NPC1L1 | Q9UHC9 | 1/20 | 0.46 |
| ▸ | TACR2 | P21452 | 1/20 | 0.44 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5578553 | 0.89 | HDAC1 (0.49) | HDAC1HDAC6HDAC8TACR1OPRM1 | |
| SCHEMBL5578911 | 0.85 | HDAC1 (0.49) | HDAC1HDAC6HDAC8TACR1SIGMAR1 | |
| SCHEMBL5578865 | 0.81 | HTT (0.47) | HDAC1HDAC6HDAC8OPRM1SIGMAR1 | |
| SCHEMBL5578859 | 0.77 | HDAC1 (0.46) | HDAC1HDAC6HDAC8TACR1SIGMAR1 | |
| SCHEMBL13209389 | 0.76 | HDAC1 (0.47) | HDAC1HDAC6HDAC8TACR1NPC1L1 | |
| SCHEMBL5578503 | 0.76 | HDAC1 (0.50) | HDAC1HDAC6HDAC8TACR1 | |
| SCHEMBL2801717 | 0.76 | HDAC1 (0.65) | HDAC1HDAC6HDAC8TACR1NPY5R | |
| SCHEMBL5579057 | 0.74 | HDAC1 (0.48) | HDAC1HDAC6HDAC8TACR1OPRM1 | |
| SCHEMBL30733409 | 0.74 | HDAC1 (0.59) | HDAC1HDAC6HDAC8SIGMAR1 | |
| SCHEMBL20954985 | 0.73 | HDAC1 (0.67) | HDAC1HDAC6HDAC8TACR1NPC1L1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070254903-A1 | Novel Spiroindoline or Spiroisoquinoline Compounds, Methods of Use and Compositions Thereof | ARENA PHARMACEUTICALS, INC. (US) | 2007-11-01 | — | — | US | claimed |
| WO-2005063745-A9 | NOVEL SPIROINDOLINE OR SPIROISOQUINOLINE COMPOUNDS, METHODS OF USE AND COMPOSITIONS THEREOF | ARENA PHARM INC (US) | 2007-02-01 | — | — | WO | claimed |
| US-20070254903-A1 | Novel Spiroindoline or Spiroisoquinoline Compounds, Methods of Use and Compositions Thereof | ARENA PHARMACEUTICALS, INC. (US) | 2007-11-01 | — | — | US | disclosed |
| US-20070254903-A1 | Novel Spiroindoline or Spiroisoquinoline Compounds, Methods of Use and Compositions Thereof | ARENA PHARMACEUTICALS, INC. (US) | 2007-11-01 | — | — | US | disclosed |
| US-20070254903-A1 | Novel Spiroindoline or Spiroisoquinoline Compounds, Methods of Use and Compositions Thereof | ARENA PHARMACEUTICALS, INC. (US) | 2007-11-01 | — | — | US | disclosed |
| WO-2005063745-A9 | NOVEL SPIROINDOLINE OR SPIROISOQUINOLINE COMPOUNDS, METHODS OF USE AND COMPOSITIONS THEREOF | ARENA PHARM INC (US) | 2007-02-01 | — | — | WO | disclosed |
| WO-2005063745-A9 | NOVEL SPIROINDOLINE OR SPIROISOQUINOLINE COMPOUNDS, METHODS OF USE AND COMPOSITIONS THEREOF | ARENA PHARM INC (US) | 2007-02-01 | — | — | WO | disclosed |
| EP-1716148-A2 | NOVEL SPIROINDOLINE OR SPIROISOQUINOLINE COMPOUNDS, METHODS OF USE AND COMPOSITIONS THEREOF | Arena Pharmaceuticals, Inc. (US) | 2006-11-02 | — | — | EP | disclosed |
| WO-2005063745-A2 | NOVEL SPIROINDOLINE OR SPIROISOQUINOLINE COMPOUNDS, METHODS OF USE AND COMPOSITIONS THEREOF | ARENA PHARMACEUTICALS, INC. (US) | 2005-07-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070254903-A1 | Novel Spiroindoline or Spiroisoquinoline Compounds, Methods of Use and Compositions Thereof | REN, AVPR2, RECQL | HDAC1 885/4885HDAC6 767/4885HDAC8 2130/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.